Yakun Wang

Yakun Wang

Auto-generated profile, based on publicly available information

Yakun Wang

Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumor, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
QZQi Zhang
Qi Zhang
YWYakun Wang
Yakun Wang
CQChangsong Qi
Changsong Qi
LSLin Shen
Lin Shen
JLjian Li
jian Li

4 March 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CLChang Liu
Chang Liu
JLJiarui Li
Jiarui Li
DLDan Liu
Dan Liu
PZPanpan Zhang
Panpan Zhang
MZMiao Zhang
Miao Zhang
SLShen Lin
Shen Lin
Purpose: The aim of the study was to evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an “off-the-shelf” allogeneic B7-H3–targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy, in patients with pretreated, advanced B7-H3–positive solid tumors. Patients and Methods: In this first-in-human, phase I, dose-escalation study (NCT06372236), 10 patients with advanced solid tumors (including gastric, colorectal, hepatocellular, ovarian, and neuroendocrine cancers) were enrolled. Following lymphodepletion chemotherapy (cyclophosphamide and fludarabine), patients received UTAA06 infusion across three dose levels (5 × 108, 8 × 108, or 1 × 109 cells). The primary endpoint was safety. Secondary endpoints included pharmacokinetics and antitumor efficacy. Results: UTAA06 demonstrated a manageable safety profile; no GVHD was observed, and cytokine release syndrome was limited to two transient grade 1 events. A single dose-limiting toxicity (grade 3 pneumonitis) was reported in one patient at the 5 × 108 cell dose level. Although UTAA06 demonstrated signals of biological activity, including transient reductions in serum tumor markers in 50% of patients, no objective response by RECIST v1.1 criteria was observed. Further analysis identified that the limited CAR T-cell persistence was likely driven by subclinical host-versus-graft rejection. Conclusions: This study provides clinical proof of concept for allogeneic B7-H3–targeted CAR-Vδ1T cells as a safe platform with low risk of GVHD and demonstrable biological activity in solid tumors. However, clinical efficacy was constrained by limited cellular persistence caused by host immune rejection. Future strategies are required to enhance the durability and therapeutic potential of this allogeneic approach.

17 June 2026
Verified
Other
Open access
CLChang Liu
Chang Liu
JLJiarui Li
Jiarui Li
DLDan Liu
Dan Liu
PZPanpan Zhang
Panpan Zhang
MZMiao Zhang
Miao Zhang
SLShen Lin
Shen Lin
Purpose:The aim of the study was to evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an “off-the-shelf” allogeneic B7-H3–targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy, in patients with pretreated, advanced B7-H3–positive solid tumors.Patients and Methods:In this first-in-human, phase I, dose-escalation study (NCT06372236), 10 patients with advanced solid tumors (including gastric, colorectal, hepatocellular, ovarian, and neuroendocrine cancers) were enrolled. Following lymphodepletion chemotherapy (cyclophosphamide and fludarabine), patients received UTAA06 infusion across three dose levels (5 × 108, 8 × 108, or 1 × 109 cells). The primary endpoint was safety. Secondary endpoints included pharmacokinetics and antitumor efficacy.Results:UTAA06 demonstrated a manageable safety profile; no GVHD was observed, and cytokine release syndrome was limited to two transient grade 1 events. A single dose-limiting toxicity (grade 3 pneumonitis) was reported in one patient at the 5 × 108 cell dose level. Although UTAA06 demonstrated signals of biological activity, including transient reductions in serum tumor markers in 50% of patients, no objective response by RECIST v1.1 criteria was observed. Further analysis identified that the limited CAR T-cell persistence was likely driven by subclinical host-versus-graft rejection.Conclusions:This study provides clinical proof of concept for allogeneic B7-H3–targeted CAR-Vδ1T cells as a safe platform with low risk of GVHD and demonstrable biological activity in solid tumors. However, clinical efficacy was constrained by limited cellular persistence caused by host immune rejection. Future strategies are required to enhance the durability and therapeutic potential of this allogeneic approach.

17 June 2026
Verified
Other
Open access
CLChang Liu
Chang Liu
JLJiarui Li
Jiarui Li
DLDan Liu
Dan Liu
PZPanpan Zhang
Panpan Zhang
MZMiao Zhang
Miao Zhang
SLShen Lin
Shen Lin
Supplementary Table 1 Final Product Release Criteria for UTAA06 Supplementary Table 2 Representativeness of Study Participants Supplementary Table 3 Baseline Characteristics and Clinical Outcomes of Individual Patients Supplementary Table 4 Characteristics of UTAA06 Products Supplementary Table 5 Serum Tumor Marker Kinetics

1 January 2026 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
HLHua Liu
Hua Liu
HXHongmei Xu
Hongmei Xu
YWYakun Wang
Yakun Wang
ZLZimin Liu
Zimin Liu
JWJia Wei
Jia Wei
XZxiaotian zhang
xiaotian zhang
Hua L, et al. J Gastric Cancer. 2026 ;26:e27. https://doi.org/10.5230/jgc.2026.26.e27

17 June 2026
Verified
Other
Open access
PDF file
CLChang Liu
Chang Liu
JLJiarui Li
Jiarui Li
DLDan Liu
Dan Liu
PZPanpan Zhang
Panpan Zhang
MZMiao Zhang
Miao Zhang
SLShen Lin
Shen Lin
Supplementary Figure 1 Specificity profiling of the anti-B7-H3 scFv using the Membrane Proteome Array (MPA). Supplementary Figure 2 Study Dose-Escalation Schema. Supplementary Figure 3 Association of Peak CAR-T Cell Expansion (Cmax) with Clinical Outcomes. Supplementary Figure 4 Lymphocyte Reconstitution Dynamics Following UTAA06 Infusion. Supplementary Figure 5 Longitudinal Serum Cytokine Dynamics Following UTAA06 Infusion. Supplementary Figure 6 Association of Cytokine Fold-Change with Clinical Outcomes. Supplementary Figure 7 Host CD8+ Activation and CAR-T Copy Number Kinetics for Individual Patients. Supplementary Figure 8 Longitudinal analysis of NK cell activation and inhibitory markers in patient P10.